DR. ALEXANDER EBENEZAR

DR. NAGBHUSHAN CHOUGULE, DR. VIVEK WANI

Abstract

Bevacizumab is an inhibitor of VEGF to treat various retinal vascular disorders.Inhibition of VEGF in the systemic circulation can be associated with thrombogenicity. MI can be a potential side effect of bevacizumab.Objective:To assess the incidence of MI among patients receiving IV bevacizumab Method:Single center,noncomparative prospective study.Subjects who received IVB for various retinal disorders between Feb2019 and Feb 2020 were regularly asked during the follow ups about any heart illness Results:A total 132 patients received IVB for retinal vascular diseases.92 patients received single injection,32 received two IVB each,5 received three IVB and 2 got five injections each.1 male patient out of 132(0.75%) developed MI four months after the last IVB who received two IVBs over a period of two Months and was treated successfully in our hospital Conclusion: prevelance of MI is difficult to assess due to patients follow up after MI and due to admission in various hospitals